Subtype
Breast Adenocarcinoma
CI-CAN-00002035Explore in graph →
686 active trials9 approved drugs104 evidence items
Loading cancer entity…
Subtype
CI-CAN-00002035Explore in graph →
Clinical trials
1,713 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (278)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03644186 | To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)(TOUCH) | completed | Phase 2 | 147 | ETOP IBCSG Partners FoundationNETWORK | 4 | Aug 26, 2026 | clinicaltrials |
| NCT06533826 | TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd(TRADE DXd) | recruiting | Phase 2 | 357 | Ana C Garrido-Castro, MDOTHER | 1 | Aug 26, 2026 |
| clinicaltrials |
| NCT06891833 | A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer | recruiting | Phase 2 / Phase 3 | 985 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07786428 | Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC(DETENTE-1) | not yet recruiting | Phase 2 | 60 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07787338 | SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast Cancer | not yet recruiting | Phase 2 | 80 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07788222 | Sacituzumab Govitecan and Q901 in Advanced TNBC | not yet recruiting | Phase 2 | 48 | Yonsei UniversityOTHER | 0 | Aug 26, 2026 | clinicaltrials |
| NCT06067503 | Biomarkers to Detect Endocrine Therapy Resistance | recruiting | Phase 2 | 8 | University of Wisconsin, MadisonOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07102381 | A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer(EmpowHER 208) | recruiting | Phase 2 | 125 | Jazz PharmaceuticalsINDUSTRY | 3 | Aug 25, 2026 | clinicaltrials |
| NCT05501704 | ETHAN - ET for Male BC | recruiting | Phase 2 | 60 | Jose Pablo LeoneOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07596212 | BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder | not yet recruiting | Phase 1 / Phase 2 | 100 | University of Illinois at ChicagoOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07743190 | A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)(NeoTILs) | recruiting | Phase 2 | 55 | Medical University of South CarolinaOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05593094 | A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 210 | Hoffmann-La RocheINDUSTRY | 7 | Aug 21, 2026 | clinicaltrials |
| NCT06441890 | BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer(BRE-10) | recruiting | Phase 2 | 28 | University of Illinois at ChicagoOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07321015 | A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance(Fzp-MA-TNBC) | recruiting | Phase 2 | 72 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06027268 | Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer(ToPCourT) | active not recruiting | Phase 2 | 36 | Wake Forest University Health SciencesOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07191717 | Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial | recruiting | Phase 2 | 42 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07459673 | HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission | recruiting | Phase 2 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04550494 | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations | active not recruiting | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04893109 | ATEMPT 2.0: Adjuvant T-DM1 vs TH | recruiting | Phase 2 | 500 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05545150 | Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study | completed | Phase 2 | 113 | Northwestern UniversityOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05919108 | Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers | recruiting | Phase 2 | 30 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07115043 | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 120 | AstraZenecaINDUSTRY | 4 | Aug 19, 2026 | clinicaltrials |
| NCT06685796 | A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer | completed | Phase 2 | 65 | BeBetter Med IncINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06910072 | Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer(UPGRADE-TNBC)(UPGRADE-TNBC) | enrolling by invitation | Phase 2 / Phase 3 | 32 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07544056 | A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer | recruiting | Phase 2 / Phase 3 | 446 | BeBetter Med IncINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT01266642 | Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer | active not recruiting | Phase 2 | 301 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04895709 | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,109 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 17, 2026 | clinicaltrials |
| NCT06358573 | Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK | recruiting | Phase 2 | 61 | Swiss Cancer InstituteOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT07768436 | A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer | recruiting | Phase 2 | 76 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05985655 | Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors(ELUCIDATE) | recruiting | Phase 1 / Phase 2 | 230 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 13, 2026 | clinicaltrials |
| NCT06399757 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 100 | Apollo Therapeutics LtdINDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07762924 | Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Following Breast-Conserving Surgery | recruiting | Phase 2 | 234 | Fudan UniversityOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04768426 | Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer | recruiting | Phase 2 | 40 | Stanford UniversityOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06525766 | Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer | recruiting | Phase 2 | 35 | Mayo ClinicOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05706129 | A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 270 | Lumara Bio Oncologics GmbHINDUSTRY | 2 | Aug 11, 2026 | clinicaltrials |
| NCT07044310 | 5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss | recruiting | Phase 2 | 38 | Mayo ClinicOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07752550 | Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer | not yet recruiting | Phase 2 | 120 | Harbin Medical UniversityOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05721248 | STOP-HER2: Stopping Trastuzumab in HER2+ MBC | active not recruiting | Phase 2 | 82 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06176261 | DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs | recruiting | Phase 2 | 58 | Nancy Lin, MDOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06439693 | The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer | recruiting | Phase 2 | 72 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05318469 | Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 34 | Yuan YuanOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07552181 | Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer | not yet recruiting | Phase 2 | 50 | Yuan YuanOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT03742102 | A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer(BEGONIA) | active not recruiting | Phase 1 / Phase 2 | 243 | AstraZenecaINDUSTRY | 6 | Aug 4, 2026 | clinicaltrials |
| NCT05579366 | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)(RAINFOL-01) | recruiting | Phase 1 / Phase 2 | 884 | GenmabINDUSTRY | 3 | Aug 4, 2026 | clinicaltrials |
| NCT06195306 | Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction | recruiting | Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07017673 | Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer | recruiting | Phase 2 | 34 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07078604 | A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer | recruiting | Phase 2 | 20 | University of WashingtonOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07739485 | Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study(GBCF003) | recruiting | Phase 1 / Phase 2 | 30 | Liu ShuOTHER | 1 | Aug 4, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 26, 2026source: clinicaltrials